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Abstract: Background: Many studies suggest oxidative stress as an early feature of Alzheimer’s Disease (AD). 
However, evidence of established oxidative stress in AD peripheral cells is still inconclusive, possibly due to 
both, differences in the type of samples and the heterogeneity of oxidative markers used in different studies.  
Objective: The aim of this study was to evaluate blood-based redox alterations in Alzheimer’s Disease in order 
to identify a peculiar disease profile.  
Method: To that purpose, we measured the activity of Superoxide Dismutase, Catalase and Glutathione Peroxi-
dase both in the extracellular and the intracellular blood compartments of AD, MCI and control subjects. The 
amount of an open isoform of p53 protein (unfolded p53), resulting from oxidative modifications was also 
determined.  
Results: Decreased SOD, increased GPx activity and higher p53 open isoform were found in both AD and MCI 
plasma compared to controls. In blood peripheral mononuclear cells, SOD activity was also decreased in both 
AD and MCI, and unfolded p53 increased exquisitely in younger AD males compared to controls.  
Conclusion: Overall, these data highlight the importance of considering both extracellular and intracellular 
compartments, in the determination of antioxidant enzyme activities as well as specific oxidation end-products, 
in order to identify peculiar blood-based redox alterations in AD pathology.  
Keywords: Alzheimer’s disease, antioxidant enzymes, cognitive decline, mild cognitive impairment, redox alterations, un-
folded p53. 
1. INTRODUCTION 
Alzheimer’s disease (AD), the most common cause of 
dementia in elderly population, is a progressive and neu-
rodegenerative disorder characterized by irreversible cogni-
tive and physical deterioration. Although the exact mecha-
nism of AD is still unclear, it is now well recognized that 
multiple etiological factors, including genetic and environ-
mental factors, and general lifestyle can contribute to the 
development of the disease [1].  
Although the "AD amyloid cascade hypothesis" has 
dominated thinking, modelling, diagnosis and drug devel-
opment efforts for almost twenty years [2], accumulating 
evidence underlined oxidative stress as an early event in AD 
development [3-5], preceding even plaques and tangles for- 
mation, as well as the clinical manifestation of AD [3, 6, 7]. 
 
*Address correspondence to this author at the Department of Molecular and 
Translational Medicine, University of Brescia, 25123 Brescia, Italy;  
Tel: +39-0303717509; E-mail: daniela.uberti@unibs.it  
Different end-products of peroxidation including malondial-
dehyde [8], peroxynitrite [9, 10], carbonyl groups [11], and 
advanced glycosylation end-products (AGEs) [8] have been 
described in AD brain and cerebrospinal fluid (CSF) [12-14]. 
In addition, decrease of antioxidant defense mechanisms in 
different brain regions, including the hippocampus, has been 
found in AD [15-18].  
The possibility that inefficiencies of free radicals detoxi-
fying enzymes and production of oxidative end-products can 
be early events contributing to AD development, brings up 
the idea that those enzymes might be also investigated as 
potential biomarkers of the disease. On the other hand, an 
evident and quantifiable level of oxidative stress in AD pe-
ripheral cells and fluids still has to be unequivocally demon-
strated. At this regard, a recent meta-analysis study reported 
that peripheral total protein oxidative damage is not a feature 
of AD [19], while specific oxidized end-products may high-
light peculiar redox changes in AD. Accordingly, oxidation 
of low density lipoproteins was found considerably increased 
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in AD as demonstrated by different studies [20-24], likely 
reflecting a pro-oxidative environment targeting more spe-
cifically a lipid fraction rather than a generalized pattern of 
proteins. No differences in term of oxidative-markers, such 
as 4-hydroxy-2-nonenal (HNE), 3-NitroTyrosine (3NT) and 
Protein Carbonyl (PC), were found in immortalized lympho-
cytes derived from either sporadic AD or healthy subjects 
[25]. It is worth noting, however, that the same AD lympho-
cytes showed an increased nitration at the tyrosine residues 
of the p53 protein that modifies its tertiary structure towards 
an unfolded conformation, pointing out this modified form 
of p53 as a useful biomarker of the presence of ongoing oxi-
dative stress [25, 26]. These findings suggest that AD pe-
ripheral cells may show fine and specific redox state altera-
tions.  
Oxidative stress is widely invoked in conditions ranging 
from inflammation and aging to complex diseases, and the 
specificity of the oxidative stress response in a given disease 
is generally very poorly understood. In addition limited in-
sights into the reciprocal influences between extracellular 
and intracellular compartment in the redox changes are 
available.  
This study was aimed to clarify the potential usefulness 
of measuring redox alterations in peripheral blood as poten-
tial biomarkers for AD pathology. In particular, we chose to 
study redox potential alterations by a double approach: i) 
measuring both the activity of three enzymes: Superoxide 
Dismutase (SOD), Catalase (CAT) and Glutathione Peroxi-
dase (GPx), involved in ROS/RNS progressive detoxifica-
tion and the amount of unfolded p53 isoform, resulting from 
peroxynitrite modifications [25], and ii) evaluating both the 
extracellular and the intracellular blood compartment, to 
identify which one of them best highlights an altered redox 
profile in Alzheimer.  
2. MATERIALS AND METHODS  
2.1. Subjects 
43 patients with Mild Cognitive Impairment (MCI), 53 
individuals with probable dementia of Alzheimer’s type 
(AD) and 44 cognitively healthy subjects (CHS) were en-
rolled at the Unit of Neurology of two different Hospitals: 
Álvarez Buylla Hospital and Cabueñes Hospital of Asturias 
(Spain). Table 1 reports the demographic and clinical profile 
of the three groups of participants. Subjects received a diag-
nosis of probable or possible AD according to NINCDS/ 
ADRDA criteria [27], whereas MCI diagnosis followed the 
criteria of Petersen when there was evidence of memory im-
pairment, preservation of general cognitive and functional 
abilities and absence of diagnosed dementia [28]. Healthy 
voluntaries recruited from routine controls had to meet the 
following criteria: 1) no history of past or current psychiatric 
or neurologic disorders, and 2) a score higher than 26 in the 
Mini-Mental State Examination (MMSE). All patients un-
derwent neuroimaging and neuropsychological assessment, 
such as the Folstein version of MMSE. In addition, depend-
ing the patient's clinical profile other tests of personalized 
assessment were performed. None of the subjects studied 
was taking antioxidant supplements. Also, subjects with 
acute comorbidities were excluded from the study. The re-
search protocol was approved by the Clinical Research Ethi-
cal Committee of Asturias (n. 31/09; 98/10). All patients or 
their families provided written informed consent for the par-
ticipation in this study. Blood samples were collected in the 
morning and centrifuged immediately. Plasma and peripheral 
blood mononuclear cells (PBMCs) were obtained by Ficoll-
Hypaque density gradient centrifugation (GE Healthcare, 
Little Chalfont, United Kingdom), aliquoted and stored at -
80°C until measurement.  
Table 1. Demographic and clinical profile of the subjects. Demographic and clinical variables and genotype frequency of the ApoE 
polymorphisms of all the subjects. N: number; M: male; F: female; L.O.I.: length of illness; MMSE: Mini-Mental State Examina-
tion. Data are expressed as mean ± standard deviation (SD). For the genotype frequency values are expressed as number (%).  
 CHS MCI AD 
n (M; F) 44 (24; 20) 43 (23; 20) 53 (13 ; 40) 
Mean age ± SD (years) 71.02 ± 8.49 75.12 ± 6.36 77.72 ± 7.73 
MMSE 29.20 ± 0.90 26.47 ± 2.15 22.57 ± 3.17 
CDR 0 0.5 1 
Disease onset  71.7±6.49 71.67 ±8.27 
L.O.I (months)  24.5 ± 14.36 26.8±13.25 
ε2/ε3 ND 0% 0.03% 
ε3/ε3 ND 76% 53% 
ε3/ε4 ND 16% 26% 
ε2/ε4 ND 0% 0% 
ε4/ε4 ND 0.03% 13% 
Abbreviations: N, number of individuals; M, male; F, female; SD, standard deviation; MMSE, Mini Mental State Examination; CHS, age-matched cogni-
tively healthy subjects; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; L.O.I., Length of Illness. 
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2.2. Superoxide Dismutase Activity 
SOD activity was measured following the inhibition of 
epinephrine oxidation, according to McCord method [29].  
25 µg of PBMC’s protein extracts or 10 µl of plasma and 5 
μl of epinephrine 0,1 M (Sigma Aldrich, St Louis, MO, 
USA) were added to a final volume of 200 µl of G buffer 
(0.05 M glycine and 0.1 M NaCl at pH 10.34), and the reac-
tion was monitored measuring the decrease of absorbance at 
480 nm. The activity of purified SOD enzyme (3000 U/mg 
Sigma Aldrich, St Louis, MO, USA) was also measured in 
each experiment as a positive control. Data were expressed 
as Units/ml for plasma and Units/mg of protein using the 
molar extinction coefficient of 4.02 at 480 nm.  
2.3. Catalase Activity 
Catalase activity was measured monitoring the decompo-
sition of H2O2 according to Shangari and O’Brien [30]. In 
particular 20 µg of PBMC’s protein extracts or 5 µl of 
plasma were incubated in a final volume of 100 µl of sub-
strate (65µM hydrogen peroxide in 6.0 mM PBS buffer pH 
7.4) at 37°C for 60 s. The enzymatic reaction was stopped by 
the addition of 100 µl of 32.4 mM ammonium molybdate 
(Sigma Aldrich, St Louis, MO, USA) and measured at 
405nm. The results were extrapolated by a standard curve 
(ranging from 12U/ml to 0,25 U/ml) performed with purified 
CAT enzyme (20100 U Sigma Aldrich, St Louis, MO, 
USA), and expressed as Units/ml for plasma and Units/mg of 
protein for PBMCs.  
2.4. Glutathione Peroxidase Activity 
The assay was performed in accordance with Awasthi  
et al. [31], measuring NADPH oxidation at 340nm in the 
reaction that involved oxidation of glutathione reduced 
(GSH) to glutathione oxidized (GSSG) followed by its re-
duction by glutathione reductase (GR). 20 µg of PBMC’s 
protein extracts or 5 µl plasma were mixed with a reaction 
mix (final volume 200 µl) containing 50 mM PBS with 0.4 
mM EDTA, pH 7.0; 1.0 mM sodium azide solution; 1.0 mg 
β – NADPH; 100U/ml GR, 200 mM GSH and 10µl of 
0.042% hydrogen peroxide. The activity of purified GPx 
enzyme (116 U/mg) was also measured in each experiment 
as positive control. All the reagents were purchased by 
Sigma Aldrich, St Louis, MO, USA. GPx activity was meas-
ured as nmol NADPH oxidized to NADP+/mg protein or ml 
plasma/min by using the molar extinction coefficient of 
0.00622 at 340nm, and the data were expressed as U/ml or 
U/mg.  
2.5. Protein Expression of Antioxidant Enzymes 
SOD3, GPX3 and CAT protein amounts were measured 
in plasma of CHS, MCI and AD groups by using commercial 
Elisa kit (Cloud-Clone Corp., Houston, USA). Results were 
extrapolated by standard curves and each samples have been 
performed at least in triplicate. Data were expressed as pg/ml 
for SOD3 and as ng/ml for GPX3 and CAT, as suggested by 
the commercial kit.  
2.6. p53 Unfolded Isoform Analysis 
p53 unfolded isoform was analysed by direct Enzyme-
Linked Immunosorbent Assay (ELISA) using the conforma-
tional antibody PAb240 (Neomarkers-Lab Vision,Fremont, 
CA, USA). This antibody recognizes an epitope masked 
when the protein is in its native conformation and accessible 
only when the tertiary structure is unfolded [25, 26, 32, 33]. 
Briefly, 100 µg of non-denaturated protein extracts, quanti-
fied with Bradford protein assay, or control peptide at differ-
ent concentration ranging from 125 ng to 7,8 ng were coated 
on a plate overnight at 4°C. Anti-p53 Pab 240 antibody 
(1:150) was incubated for 2 h at 37°C, followed, after wash-
ing, by 1h at RT of secondary anti-mouse antibody conju-
gated with peroxidase. Finally, 100 µl of TMB (3,3,5,5-
tetramethylbenzidine) substrate was added and the reaction 
was stopped with 100 µl of sulphuric acid 2 M. Optical den-
sity (OD) was measured at 450 nm. Results were extrapo-
lated by standard curve and expressed as ng of unfolded 
p53/100 μg of protein or ng of unfolded p53/ ml.  
2.7. Statistical Evaluation 
All the assays were performed in triplicate. Data were 
expressed as the mean value ± 95 % confidence interval (CI) 
or as the mean value ± S.E.M, according to the experiment. 
Statistical significance of differences was determined by one 
way ANOVA, followed by the Bonferroni test. Student’s  
t-test was also used to compare values in different groups. 
For the correlation analysis a parametric method was used 
and data were analysed by simple linear regression. Differ-
ences were considered significant for a p-value <0.05. 
3. RESULTS  
3.1. Antioxidant Enzymatic Activity in Plasma from AD, 
MCI and Control Groups 
Enzymatic activity of SOD, CAT and GPx was evaluated 
in the extracellular compartment [ext] derived from 53 AD, 
43 MCI and 44 age-matched cognitively healthy subjects 
(CHS). All the data are reported in Fig. (1). When consider-
ing SOD and GPx enzymatic activity, both AD and MCI 
group showed a similar trend when compared to the CHS 
cohort: SOD[ext] was significantly lower (MCI 251,55 ± 
23,49; AD 254,05 ± 20,59 vs.. CHS 550,31 ± 33,35 
p<0,0001 and p<0,001 respectively) (Fig. 1A), while 
GPx[ext] activity was found higher (MCI 232,81 ± 7,4; AD 
226,06 ± 8,01 vs.. CHS 176,94 ± 8,71 p<0.0001 and p<0.001 
respectively) (Fig. 1C). Differently, CAT[ext] activity re-
sulted lower in the AD plasma than in CHS samples (AD 
22,52 ± 1,22 vs.. CHS 30,82 ± 1,64 p<0.001), while MCI 
CAT[ext] values were not significantly different from those 
of controls (Fig. 1E). We also evaluated the protein expres-
sion of extracellular antioxidant enzymes. In particular 
SOD3, GPX3 and extracellular CAT protein amounts were 
measured in the plasma of people from CSH, AD and MCI 
groups, and no significant difference was found among the 
three groups (Fig. 2). 
To understand whether gender could affect the activity of 
extracellular enzymes, male and female sub-groups were 
also examined. In CHS group, SOD[ext] activity was signifi-
cantly lower in women (W) compared to men (M) (CHS M 
610,3 ± 45 vs. CHS W 476,2 ± 45 p <0.05), while GPx[ext] 
and CAT[ext] activity were not influenced by gender. In 
MCI and AD groups, no substantial sex-related differences
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Fig. (1). Antioxidant Enzyme activity in plasma derived from AD, MCI and control groups. The activity of SOD (A), GPx (C) and CAT 
(E) enzymes were assessed in plasma derived from MCI, AD and CHS as reported in method section. SOD[ext] activity: MCI, AD p<0,0001 
vs. CHS; GPx[ext] activity : MCI, AD p<0,0001 vs. CHS; CAT[ext] activity: AD p<0,0001 vs. CHS. SOD (B), GPx (D) and CAT (F) en-
zymes were also analysed in function of gender (MEN/WOMEN). SOD[ext] activity: MCI men (M) p<0,00001; MCI women (W) p<0.0001 
vs. respective CHS, AD M and AD W p<0,00001 vs. respective CSH; CHS W p<0,05 vs. CHS M (#); GPx[ext] activity : MCI M p<0.001and 
MCI W p<0.05 vs. respective CHS; AD M and AD W p<0,05 vs. respective CHS; CAT[ext] activity: AD M p<0.001 and AD W p<0,05 vs. 
respective CHS. 
 
Fig. (2). Superoxide dismutase, catalase and glutathione peroxidase expression.  
Antioxidant enzyme analyzed by using sandwich enzyme immunoassays for in vitro quantitative measurement of SOD3 (A), GPX3 (B) and 
extracellular catalase (C) in human plasma derived from MCI, AD and CHS. Results were extrapolated by standard curves and samples have 
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were found for SOD [ext], GPx [ext] and CAT[ext] activity 
when compared with CHS, although GPX[ext] in MCI men 
reached a higher statistical significance than in women (Fig. 
1B,D,F). Similarly, CAT[ext] in AD male displayed a lower 
p-value then AD female when compared with CHS. Such 
differences could be probably due to either the dispersion of 
values (i.e. MCI), or the numerical discrepancy in gender 
subgroups (i.e. AD: 13 M; 40 F). 
3.2. Antioxidant Enzymatic Activity in PBMCs from AD, 
MCI and Control Groups 
Antioxidant enzymatic activities were also studied in 
PBMC extracts [int] derived from AD, MCI and CHS sub-
jects (Fig. 3A,C,E) in order to evaluate the possibility that 
changes in the extracellular redox equilibrium may either 
induce or be associated to an intracellular redox change in 
the immune system [34] and this, on turn, might be relevant 
for the development of Alzheimer’s disease. Significant dif-
ferences were found for SOD[int] activity, which was sig-
nificantly lower in MCI and AD samples than in CHS, (MCI 
26,09 ± 2,16; AD 23,36 ± 2,37 vs. CHS 37,44 ± 2,77 
p<0.001, and p<0.0001 respectively) (Fig. 3A). In contrast, 
CAT[int] and GPx[int] activities did not significantly change 
among the three groups (Fig. 3C, E). These results were also 
analysed as a function of gender. We found that SOD[int] in 
men MCI showed a significantly lower activity compared to 
CHS (p <0.001), while that in women MCI did not change. 
Instead, in the AD group, only women SOD[int] exhibited a 
significant reduction with respect to the analogous CHS, 
probably due to the greater dispersion of value observed in 
the male group (Fig. 3B). No differences were found when 
gender subdivision was applied to the analysis of GPx[int] 
and CAT[int] activity (Fig. 3D,F). 
3.3. Unfolded p53 in Plasma and PBMCs from AD, MCI 
and Control Groups 
In order to evaluate an early-formed oxidative end-
product, we focused on the nitrated isoform of p53 protein, 
which undergoes to a conformational change due to the 
steric hindrance of 3-nitrotyrosines and can be detected using 
conformational specific monoclonal antibodies [25, 26]. Un-
folded p53 in plasma and PBMCs derived from AD, MCI 
and CHS was measured by ELISA immunoassay using 
PAb240 antibody, that specifically recognizes an epitope that 
is masked when the protein is in its native conformation, and 
becomes accessible only when the tertiary structure is un-
 
Fig. (3). Antioxidant Enzyme activity in PBMCs derived from AD, MCI and control groups. The activity of SOD (A), GPx (C) and 
CAT (E) enzymes were assessed in PBMCs derived from MCI, AD and CHS as reported in method section. SOD[int] activity: MCI p<0,001 
and AD p<0,0001 vs. CHS respectively. SOD (B), GPx (D) and CAT (F) enzymes were also analysed in function of gender 
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folded [32, 33]. As shown in (Fig. 3), plasma levels of un-
folded p53 were increased in both MCI and AD groups as 
compared to CHS, being anyway higher in samples from AD 
subjects (unfolded p53[ext]: MCI 5.9 ± 011, AD 6.2 ± 0.13 
vs. CHS 5.2 ± 0,10 p<0.001 and p<0.0001 respectively) (Fig. 
4A). However, PBMC levels of unfolded p53 were higher 
only in the AD group when compared with CHS (Fig. 4C) 
(unfolded p53[int]: AD 18.05 ± 0.5 vs. CHS 15.2 ± 0,5 
p<0.0001), confirming our previous results [25, 35-37]. The 
gender analysis of p53[ext] showed no differences between 
men and women in MCI. Both sexes showed increased levels 
of unfolded p53 compared with the corresponding control 
group (p<0.05), although male AD showed higher p53[ext] 
levels than female AD subjects compared to the analogous 
CHS group (p<0.001) (Fig. 4B). The male AD group high-
lighted better also the differences with CHS group in the 
intracellular compartment (Fig. 4D). In fact p53[int] showed 
in the male AD group a higher statistical significance with 
CHS (p<0.0001) than the female one (p<0.05). 
3.4. Redox Equilibrium Potential, Age and Cognitive 
Status  
We then attempted to highlight a possible relationship 
between the progression of the disease and the extracellular 
and intracellular redox equilibrium. Correlation studies be-
tween either the antioxidant enzyme activities (Fig. 5) or 
unfolded p53 (Fig. 6) and the cognitive status, measured as 
MMSE score, or the age, were performed. Among antioxi-
dant enzymes, only SOD activity showed a significant corre-
lation with both the cognitive status and the age of subjects. 
Both SOD[ext] and SOD[int] activity statistically well corre-
lated with MMSE score (SOD[ext] p=0,0004, r2=0,09; 
SOD[int] p=0,0051, r2= 0,06) (Fig. 5B,F), and the age 
(SOD[ext] p=0,027, r2= 0,04; SOD[int] p=0,005, r2 0,06) 
(Fig. 5A,E). We also subdivided the cohort of subjects in 
two specific age intervals (≤75 years and > 75 years), and 
within these two groups further subdivision by gender was 
performed. Interestingly in the women CHS group, 
SOD[ext] activity was lower in the group over 75 years old 
than in the younger one (Fig. 5C). As shown in Fig. (5C,D) 
the decrease in the activity of SOD[ext] observed in MCI 
and AD with respect to CHS was statistically more impres-
sive in the younger group than in the older one independ-
ently of gender. However, when considering the gender, 
SOD[ext] activity was significantly reduced in MCI men > 
75 years old, but not in the women of the same age. When 
considering intracellular SOD activity, a significant reduc-
tion can be observed in young men MCI and women AD 
over 75 years old, when compared to their respective CHS 
group (Fig. 5H,G). This result could be due to the high dis-
persion of values within the AD younger group and the dis-
crepancy among the number of subjects within each groups 
(AD ≤ 75 years 16 (9 F; 7M); AD > 75 years 37 (31 F; 6 
M)).  
We then analysed the possible correlation between un-
folded p53 and both the cognitive status and the age of sub-
jects. Only the amount of p53[int] showed a significant in-
verse correlation with age (p<0,02, r2=0,04) (Fig. 5E), while 
unfolded p53[ext] did not correlate when all age is consid-
ered (data not shown). However, a statistically significant 
inverse correlation between unfolded p53[ext] and age was 
found when a subgroup, represented by younger men (≤75 
years) was considered (p=0,05 r2=0,16) (Fig. 6A). In particu-
lar, in both men MCI and AD ≤75 years, unfolded p53[ext] 
was found statistically higher when compared with the ana-
logue CHS (Fig. 6D), while only AD men of this age showed 
higher amounts of unfolded p53[int] (Fig. 6H).  
The increased expression of unfolded p53 [int] was sig-
nificantly correlated with dropping of cognitive decline 
(p<0,0001, r2=0,13) (Fig. 6F); while no statistical significant 
correlation was found between MMSE and unfolded 
p53[ext] when all groups of age were considered (data not 
shown). However, when the same specific subgroup previ-
ously reported (men ≤75 years) was analysed, a good inverse 
correlation between unfolded p53[ext] and MMSE score was 
found (p=0,001, r2=0,28) (Fig. 6B).  
4. DISCUSSION  
This study identified peculiar alterations in the antioxi-
dant defence systems regulating the extracellular and intra-
cellular redox state in the context of cognitive decline dis-
eases. In particular, it highlighted significant differences 
between the extracellular and the intracellular blood com-
partments in AD and MCI patients when compared to 
healthy subjects. In the extracellular compartment, the anti-
oxidant cascade, involving SOD, CAT and GPx enzymes, 
was found impaired in both AD and MCI. We observed a 
drastic reduction in SOD activity and a significant increase 
in GPx activity in both groups of patients. Also a significant 
reduction in CAT enzymatic activity was found in the AD 
group and a trend of decrease in CAT activity was also 
found in MCI plasma samples, although no statistically sig-
nificant. These three investigated antioxidant activities work 
in concert to prevent an excess of ROS/RNS production: 
SOD catalyses the dismutation of superoxide (O2
-) into oxy-
gen and hydrogen peroxide (H202), which is further degraded 
by CAT and GPx to water. It is well established that 
ROS/RNS can affect SOD enzyme and compromise its activ-
ity [38-40]. Thus, the decreased activity of SOD[ext] (also 
known as SOD3 to distinguish it from cytoplasmic SOD1 
and mitochondrial SOD2), can be explained as the result of a 
long lasting exposure to pro-oxidative environment. In fact, 
no differences were found in term of SOD3 expression be-
tween the three groups (Fig. 2). These data are in good 
agreement with those reported by Padurariu et al. [41], al-
though other authors did not find differences in the SOD 
activity in plasma from AD patients [19, 42]. Interestingly, 
the female control group had a lower SOD3 activity than 
men, that further decreased with the age ( CHS W > 75 years 
vs. CHS W ≤75 years); while no differences in term of gen-
der and age where found in the AD and MCI groups. In this 
regard, Bellanti et al. [43], demonstrated that estrogens in-
fluenced circulating redox balance by affecting cellular anti-
oxidant enzyme system. In particular the authors demon-
strated in women a linear relationship between the circulat-
ing estrogen levels and SOD activity.  
Although CAT and GPx catalyze the same reactions, 
their pathophysiological role is quite different. GPx is recog-
nized to be the major enzyme for H2O2 detoxification under 
normal conditions [44]. Since no differences were found in 
the amount of GPX3 protein (Fig. 2) among the three groups,
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Fig. (4). Unfolded p53 in plasma and PBMCs derived from AD, MCI and control groups. Unfolded p53 amount were measured in 
plasma (A) and PBMCs (C) derived from MCI, AD and CHS as reported in method section. Unfolded p53[ext]: MCI p< 0,001 and AD 
p<0,0001 vs. CHS respectively; unfolded p53[int]: AD p<0,0001 vs. CHS. Data analysed in function of gender (MEN/WOMEN) of p53[ext] 
(B) and p53[int] (D). Unfolded p53[ext]: MCI M and MCI W p<0,05 vs. respective CHS; AD M p<0,001and AD W p<0.05 vs. respective 
CHS; unfolded p53[int]: AD M p<0.0001 and AD W p<0,05 vs. CHS. 
 
the increase of its activity observed in AD and MCI subjects 
could be interpreted as an adaptive attempt to counteract an 
excess of H202 and/or ONOO
- in plasma. Interestingly, Sies 
et al. [45], demonstrated that exquisitely the extracellular 
GPx isoform (one of the eight different GPx isoforms, also 
known as GPx3), is able to reduce peroxynitrite (ONOO-). 
Differently, catalase plays a significant role in protecting 
cells against severe oxidative stress [46]. Having one of the 
highest rates of turnover known, this enzyme acts counter-
acting and balancing the continual production of hydrogen 
peroxide. The decrease in the extracellular catalase activity 
(which is one of the 5 different CAT isoforms) observed 
only in AD subjects would be consistent with an impairment 
in these patients in the removal of H2O2 that in turn could 
lead to a microenvironmental redox state perturbation. Our 
results are consistent with those previously reported by Puer-
tas et al. [42], who also observed a significant decreased 
CAT activity in AD subjects, although in that study was also 
reported a decreased GPx activity. On the other hand, other 
studies showed either an increase or no changes of CAT and 
GPx activity in AD [6, 47-49], indicating the existence of 
controversy on this point.  
When considering the intracellular compartment, SOD 
(SOD1, SOD2), but not GPx or CAT activity, was signifi-
cantly reduced in PBMCs of both AD and MCI patients. 
This result confirm our previous findings in immortalized 
lymphocytes derived from familiar and sporadic AD [25], 
and suggest SOD activity impairment to be an early event in 
the development of the disease. 
The differences between the extracellular and the intra-
cellular blood compartments observed in this study can be 
explained, at least partially, taking into account that each 
compartment is endowed with its own antioxidant enzyme 
isoforms, encoded by different genes [50], and that the two 
compartments can be differently perturbed by endogenous 
and/or exogenous oxidants.  
The extracellular and intracellular redox equilibrium in-
fluences the structure, stability, and function of macromole-
cules that reside within each compartment. Among them, 
both p53 protein structure and activity have been suggested 
to be particularly affected by the redox state [26, 32]. We 
have previously demonstrated a positive correlation between 
SOD activity and nitrated-p53 isoform in immortalized B-
lymphocytes derived from AD and from control subjects 
[25]. Here we have found that a high amount of unfolded 
p53 isoform occurs in both MCI and AD plasma, while in 
the intracellular compartment only AD showed increased 
unfolded p53 levels. It is noteworthy that the major differ-
ences of extracellular and intracellular unfolded p53 ob-
served in AD subjects, compared with the CHS group, were 
found in male subjects under 75 years old. This enhancement 
in AD might be due to a progressively higher pro-oxidant 
intracellular environment that favors unfolded p53 forma-
tion. However, we cannot exclude the influence of a severely 
compromised extracellular redox state (as observed in AD) 
since both compartments may influence each other in regu-
lating and maintaining the redox steady-state and in modulat-
ing the redox signaling or perturbing normal cellular proc-
esses [34]. In this regard Vignini et al. [51], demonstrated 
that an increased nitrosative stress occured in AD compared 
with matched control subjects, and interestingly, AD males 
showed a higher peroxynitrite (ONOO-) production (25% 
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Whether or not the intracellular nitrated unfolded p53 could 
constitute a useful biomarker to discriminate between the 
early and late stage of the disease will be further demon-
strated with an ongoing follow up study on the MCI group.  
To further understand which of the examined parameters 
could better characterize the AD- related blood changes, the 
antioxidant enzyme activities as well as the amount of un-
folded p53 were correlated with both cognitive decline and 
the age of enrolled subjects. Among antioxidant enzymes, 
only SOD activity correlated with either MMSE score and 
age both extra and intra-cellularly. Also unfolded p53[int] 
inversely correlated with MMSE and age. On the other hand 
a significant positive correlation between MMSE and age 
with blood circulating unfolded p53 was found only for male 
subjects under 75 years old. Therefore, the nitrated open p53 
isoform and impaired SOD activity might be considered 
likely early biomarkers of peripheral oxidative stress occur-
ring in AD. 
CONCLUSION 
The complexity of Alzheimer’s disease (AD) and its long 
prodromal phase are challenges for early diagnosis. How-
ever, it is worth noting the importance to study biomarkers, 
in particular, in the preclinical and early phases reflecting the 
 
Fig. (5). Correlation among SOD activity with cognitive decline or age. The values of SOD[ext] activity (A,B) and SOD[int] (E,F) of all 
samples (MCI, AD and CHS) were correlated with the age (A,E) and with the corresponding values of MMSE score (B-F). SOD[ext]/AGE 
p=0.027 r2=0.04 (y=-5.03x+708.3); SOD[ext]/MMSE p=0.0004 r2=0.09 (y=17.59x-121.3); SOD[int]/AGE p=0.0051 r2=0.06 (y=-
0.56x+71.01); SOD[int]/MMSE p=0.0051 r2=0.06 (y=1.25x-3.37). Data analysed in function of gender and two specific age interval (≤75 
years and > 75 years). SOD[ext] ≤75: MCI (M/W p<0,00001/p<0.0001), AD (M/W p<0,0001) vs. CHS; SOD[ext]>75: MCI (M p<0,001), 
AD (M/W p<0,001) vs. CHS (C-D); CHS W ≤75 p<0,05 vs. CHS W >75 (#); SOD[int]≤75: MCI (M p<0,001) vs. CHS; SOD[int]>75 AD 
(W p<0,001) vs. CHS (G-H). 






































































































































































































































































p=0,027  r2 =0,04 p=0,0004  r2 =0,09
p=0,0051  r2 =0,06 p=0,0051  r2 =0,06
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pathological features of the disease. Blood-based biomarkers 
potentially provide a minimally invasive approach for this 
purpose. With regard to this topic, our data underscore the 
importance of studying both extracellular (plasma) and intra-
cellular (PBMC) blood compartments in term of antioxidant 
enzymatic activities, as well as specific oxidation end-
products, in order to identify peculiar redox alterations rep-
resentative of dynamic events occurring in cognitive decline 
diseases.  
LIST OF ABBREVIATIONS 
AD = Alzheimer’s Disease 
CAT = Catalase 
CHS = cognitively healthy subjects  
CSF = cerebrospinal fluid 
GPx = Glutathione Peroxidase 
MCI = Mild Cognitive Impairment 
 
Fig. (6). Correlation among unfolded p53 with cognitive decline or age. The values of unfolded p53[ext] (A,B) and unfolded p53[int] 
(E,F) of all samples (MCI, AD and CHS) were correlated with the age (A,E) and with the corresponding values of MMSE score (B,F). Un-
folded p53 M≤75 [ext]/AGE p=0.05 r2=0.16 (y=0.07x+1.574); unfolded p53 M≤75 [ext]/MMSE p=0.0011 r2=0.28 (y=-0.22x+11.91); un-
folded p53[int]/AGE p=0.02 r2=0.04 (y=0.084x+10.14); unfolded p53[int]/MMSE p<0.0001 r2=0.13 (y=-0.29x+23.95). Data analysed in 
function of gender and two specific age interval (≤75 years and > 75 years). Unfolded p53[ext] ≤75: MCI,AD (M) p<0.05, p<0.0001 vs. CHS 
(C-D); unfolded p53[int]≤75: ADI (M/W p<0,001/p<0.05) vs. CHS (G-H). 
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MMSE = Mini-Mental State Examination 
SOD = Superoxide Dismutase 
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